Altimmune (ALT)
NASDAQ:ALT
Want to see ALT full AI Analyst Report?
ALT Stock Chart & Stats
$3.50
$0.16(2.19%)
At close: 4:00 PM EST
$3.50
$0.16(2.19%)
Day’s Range― - ―
52-Week Range$2.56 - $7.73
Previous CloseN/A
Volume1.55M
Average Volume (3M)3.15M
Market Cap
$507.58M
Enterprise Value$207.43M
Total Cash (Recent Filing)$331.54M
Total Debt (Recent Filing)$35.85M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Aug 06, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding194,474,150
10 Day Avg. Volume2,896,372
30 Day Avg. Volume3,149,702
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue5.76K
Enterprise Value/Gross Profit-13.88
Enterprise Value/Ebitda-2.35
Forecast
1Y Price Target
$13.38Price Target Upside282.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$5.13K
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA debt-free balance sheet with roughly $284M of equity against ~$336M of assets gives durable financial flexibility. This reduces near-term refinancing pressure as programs advance, supports multi-year clinical work and CRO commitments, and helps absorb trial timing variability.
Pro Forma Cash RunwayThe oversubscribed $225M financing and stated pro forma cash of ~$535M materially lower near-term financing risk. That runway underpins global Phase III start-up, clinical supply, and pre-commercial activities, enabling execution on planned registrational timelines without immediate dilution.
Regulatory & Development ProgressBreakthrough Therapy designation plus FDA/EMA alignment on the PERFORMA protocol materially raise the program's regulatory visibility and reduce design risk. CRO engagement and planned H2 2026 start indicate tangible late-stage readiness and clearer regulatory pathway to potential approval.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~ -$72M TTM) means the company will continue to consume capital as trials advance. Even with recent financing, prolonged timelines or additional programs could require further funding, increasing dilution risk and constraining long-term investment flexibility.
Large Ongoing Losses & Minimal RevenueVery large net losses and essentially no product revenue create structural dependency on successful clinical outcomes and external financing. Without commercialization, operating leverage is absent and persistent losses will erode equity if cash consumption continues beyond planned runway.
Long, Resource‑Intensive Phase IIIThe PERFORMA Phase III’s 52‑week biopsy primary and event‑driven design mean long lead times to registrational data (readout expected in 2029). Extended timelines raise cumulative trial costs, heighten exposure to evolving competition and regulatory expectations, and delay any potential revenue.
Altimmune News
ALT FAQ
What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was $2.56 and its highest was $7.73 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is $507.58M.
When is Altimmune’s upcoming earnings report date?
Altimmune’s upcoming earnings report date is Aug 06, 2026 which is in 52 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on May 13, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.062.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune dividends here
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -0.15.
How many shares outstanding does Altimmune have?
Altimmune has 194,474,150 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went down -1.948%.
Which hedge fund is a major shareholder of Altimmune?
Currently, no hedge funds are holding shares in ALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.38 (282.14% Upside)
$13.38 (282.14% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 80%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $198.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.49%
12-Months-Change
Fundamentals
Return on Equity
-42.57%
Trailing 12-Months
Asset Growth
113.42%
Trailing 12-Months
Company Description
Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
ALT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed significant progress: strong financing ($225M offering; $535M pro forma cash), regulatory recognition (Breakthrough Therapy), alignment with FDA/EMA on the PERFORMA Phase III protocol, robust Phase II efficacy/tolerability signals, and near-term readouts (AUD topline; RESTORE enrollment). Challenges were mostly operational and expected for a late-stage biotech: higher G&A and R&D as programs advance, a wider net loss in the quarter, ongoing validation/integration of digital pathology tools, and a competitive landscape necessitating clear differentiation. Overall, the positives — especially the cash runway and Phase III readiness — materially outweigh the manageable execution and competitive risks.View all ALT earnings summariesALT Stock 12 Month Forecast
Average Price Target
$13.38
▲(282.14% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.45% Insiders
8.62% Mutual Funds
3.26% Other Institutional Investors
75.89% Public Companies and Individual Investors